Newsfeeds - Spark Newswire

1 minute read

Trevi Therapeutics Q4 EPS $(0.28) Beats $(0.30) Estimate

Today, 5:47 AM

Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.30) by 6.67 percent. This is a 46.15 percent increase over losses of $(0.52) per share from

TRVI

3 minute read

The Daily Biotech Pulse: AbbVie’s Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data

By Shanthi Rexaline

Today, 5:47 AM

Here's a roundup of top developments in the biotech space over the last 24 hours:

ABBV

2 minute read

12 Health Care Stocks Moving In Monday’s Intraday Session

By Benzinga Insights

Today, 5:47 AM

BCEL

2 minute read

Movers

12 Health Care Stocks Moving In Friday’s After-Market Session

By Benzinga Insights

Today, 5:47 AM

Gainers Trevi Therapeutics (NASDAQ:TRVI) stock moved upwards by 11.9% to $1.41 during Friday's after-market session. The market value of their outstanding shares is at $36.4 million.

ATXI

5 minute read

68 Biggest Movers From Yesterday

By Lisa Levin

Today, 5:47 AM

Gainers ECMOHO Limited (NASDAQ: MOHO) climbed 56.7% to close at $0.3650 on Wednesday after jumping 10% on Tuesday.

ADV

3 minute read

12 Health Care Stocks Moving In Wednesday’s Intraday Session

By Benzinga Insights

Today, 5:47 AM

ARDX

6 minute read

80 Biggest Movers From Yesterday

By Lisa Levin

Today, 5:47 AM

Gainers

ALBO

10 minute read

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

Today, 5:47 AM

On Thursday, 147 companies achieved new lows for the year.

AFRM

5 minute read

60 Biggest Movers From Yesterday

By Lisa Levin

Today, 5:47 AM

Gainers US Ecology, Inc. (NASDAQ: ECOL) shares surged 67.7% to close at $47.25 on Wednesday after Republic Services reported it will buy the company at $48 per share in cash.

ABST

2 minute read

Trevi Therapeutics Completes Enrollment For Phase 2b/3 PRISM Study In Chronic Pruritus In PN

By Benzinga Newsdesk

Today, 5:47 AM

Trevi Therapeutics, Inc. (NASDAQ:TRVI) is a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions. Today, Trevi

TRVI